Biosafe Group SA
Biosafe Group SA, founded in 1997 and headquartered in Eysins, Switzerland, develops, manufactures, and supplies cell processing solutions for the BioProcessing and Regenerative Medicine end-markets, operating with 51-100 employees.
- Company typePrivate
- Founded1997
- HeadquartersEysins, Switzerland
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Biosafe Group SA does
Biosafe Group SA is a privately held Swiss company founded in 1997 that develops, manufactures, and supplies solutions for cell processing, serving customers across the BioProcessing and Regenerative Medicine end-markets. The company is headquartered in Eysins, Switzerland, and operates with a workforce of 51-100 employees, positioning it as a small-to-mid-sized specialty manufacturer within a tightly regulated life sciences niche. Its focus on cell processing — the workflows used to separate, wash, concentrate, preserve, and otherwise handle cells for therapeutic and research applications — places the company in a structurally growing subsegment of the broader bioprocessing tools market that supplies both established biologics manufacturers and emerging cell-and-gene therapy developers.
Specific product details, platform architecture, and proprietary technology components are not disclosed in available sources; the firmographic record identifies the company only by its function (cell processing solutions) and end-markets. Revenue mechanics, pricing model, channel structure, and go-to-market approach are also not publicly disclosed. Given the regulated nature of the buyer base — cell therapy developers, biopharma manufacturers, and academic or clinical centers operating under GMP — the business model is most plausibly a mix of capital equipment sales plus recurring consumables and service, but this characterization is inferential and not confirmed in the available material. The data gap is material for any diligence use case and should be addressed with primary-source research before further investment conclusions are drawn.
The only ancillary data point available is a third-party market sizing reference for the broader Laboratory Ovens and Freezers category, valued at USD 6.2 billion in 2025 with a projected USD 10.83 billion by 2033 at a 7.21% CAGR. This reference is not directly attributable to Biosafe's cell processing product line and is flagged in the source as potential market context only.
Biosafe Group SA firmographics
Firmographics- Name
- Biosafe Group SA
- Website
- https://biosafe.ch
- Company type
- Private
- Founded year
- 1997
- Headcount range
- 51–100 employees
- Short description
- Biosafe Group SA, founded in 1997 and headquartered in Eysins, Switzerland, develops, manufactures, and supplies cell processing solutions for the BioProcessing and Regenerative Medicine end-markets, operating with 51-100 employees.
- Ownership category
- akta.pro rank
Biosafe Group SA industry classification
Industry- Product category
- Bioprocessing Equipment
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers) (HLAGAIAG)
- akta.pro secondary industries
- Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling) (HLAAAJAF)
Keywords
Where Biosafe Group SA is headquartered
LocationHeadquarters
- HQ city
- Eysins
- HQ country
- Switzerland
- HQ region
- Europe
Markets served
Biosafe Group SA business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Biosafe Group SA product offering
Product offeringCore offering
Biosafe Group SA develops, manufactures, and supplies innovative solutions for cell processing, targeted at customers in BioProcessing and Regenerative Medicine. The company's offering centers on equipment and consumables used to process cells for therapy development and biomanufacturing workflows, with a focus on enabling reproducible, scalable cell processing steps required by cell therapy developers and biopharmaceutical manufacturers.
Differentiator
Problem solved
Functional benefit
Products and services
- Cell Processing Solutions for BioProcessing and Regenerative Medicine A line of innovative cell processing solutions developed and manufactured by Biosafe Group SA, supplied to biopharmaceutical manufacturers, cell therapy developers, and regenerative medicine research organizations for use in BioProcessing and Regenerative Medicine workflows.
Companies that use Biosafe Group SA
Customer profileIdeal customer profiles2 records
Biosafe Group SA technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Biosafe Group SA partnerships and signals
Strategic signalScale indicators3 records
Biosafe Group SA competitors and assessment
Company assessmentBroad incumbents
- Cytiva (formerly GE Healthcare Life Sciences): Cytiva is a global bioprocessing supplier offering cell therapy workflow solutions, single-use systems, and instruments; it overlaps directly with Biosafe's cell processing focus and is referenced in the company data set.
- Sartorius AG: Sartorius supplies upstream bioprocessing equipment, single-use bioreactors, and cell therapy manufacturing solutions, serving many of the same biopharma and cell-therapy manufacturers that Biosafe targets.
- Thermo Fisher Scientific (Cell Therapy): Thermo Fisher's bioproduction and cell therapy services include cell processing equipment, consumables, and contract manufacturing, directly relevant to Biosafe's therapeutic cell-processing business.
- Lonza Group: Lonza is a leading CDMO and supplier of cell and gene therapy manufacturing technologies, including automated cell processing platforms, and operates out of Switzerland like Biosafe.
- Beckman Coulter Life Sciences: Beckman Coulter Life Sciences offers automated cell processing and counterflow centrifugation systems (e.g., Cell Washers, isolation instrumentation) used in cell therapy workflows comparable to Biosafe's offerings.
Direct peers
- Miltenyi Biotec: Miltenyi Biotec specializes in cell separation and processing instruments (e.g., Prodigy, CliniMACS) used in cell and gene therapy manufacturing, directly competing in Biosafe's core cell-processing equipment category.
Emerging players
- CellGenix GmbH: CellGenix supplies GMP-grade cell processing reagents, cytokines, and ancillary materials for cell and gene therapy manufacturing, overlapping with Biosafe on the consumables and workflow side of cell processing.
- STEMCELL Technologies: STEMCELL Technologies develops cell isolation and processing instruments, reagents, and automation tools used in regenerative medicine and cell therapy, making it a peer in Biosafe's adjacent niche.
- PBS Biotech: PBS Biotech offers single-use bioreactors and cell culture systems for cell and gene therapy manufacturing, providing overlapping upstream cell-processing capability for similar end customers as Biosafe.
- RoosterBio: RoosterBio provides human mesenchymal stem cell platforms and bioprocess media used in regenerative medicine manufacturing, supplying cell-processing workflows that intersect with Biosafe's customer base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Biosafe Group SA social profiles
Digital presenceBiosafe Group SA financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biosafe Group SA leadership team
Management profileNumber of profiles
Biosafe Group SA funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biosafe Group SA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biosafe Group SA
What does Biosafe Group SA do?
Biosafe Group SA develops, manufactures, and supplies innovative solutions for cell processing, targeted at customers in BioProcessing and Regenerative Medicine. The company's offering centers on equipment and consumables used to process cells for therapy development and biomanufacturing workflows, with a focus on enabling reproducible, scalable cell processing steps required by cell therapy developers and biopharmaceutical manufacturers.
When was Biosafe Group SA founded?
Biosafe Group SA was founded in 1997. It employs 51 to 100 people.
Where is Biosafe Group SA based?
Biosafe Group SA is headquartered in Eysins, Switzerland, in the Europe region.
Who are Biosafe Group SA's main competitors?
Broad incumbents on record are Cytiva (formerly GE Healthcare Life Sciences), Sartorius AG, Thermo Fisher Scientific (Cell Therapy), Lonza Group and Beckman Coulter Life Sciences. Miltenyi Biotec is listed as a direct peer. Emerging players are CellGenix GmbH, STEMCELL Technologies, PBS Biotech and RoosterBio.
Does Biosafe Group SA have an API?
No public API is recorded for Biosafe Group SA.
What industry is Biosafe Group SA in?
Biosafe Group SA's product category is Bioprocessing Equipment. Its primary akta.pro industry code is HLAGAIAG, Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers), with a secondary code of HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream). Its NAICS code is 541714 and its SIC code is 3841.